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Abstract
Background: "Loss of function" alterations in CCAAT/Enhancer Binding Proteinδ (C/EBPδ) have been reported in a 
number of human cancers including breast, prostate and cervical cancer, hepatocellular carcinoma and acute myeloid 
leukemia. C/EBPδ gene transcription is induced during cellular quiescence and repressed during active cell cycle 
progression. C/EBPδ exhibits tumor suppressor gene properties including reduced expression in cancer cell lines and 
tumors and promoter methylation silencing.
We previously reported that C/EBPδ expression is inversely correlated with c-Myc (Myc) expression. Aberrant Myc
expression is common in cancer and transcriptional repression is a major mechanism of Myc oncogenesis. A number
of tumor suppressor genes are targets of Myc transcriptional repression including C/EBPα, p15INK4, p21CIP1, p27KIP1
and p57KIP2. This study investigated the mechanisms underlying Myc repression of C/EBPδ expression.
Results: Myc represses C/EBPδ promoter activity in nontransformed mammary epithelial cells in a dose-dependent 
manner that requires Myc Box II, Basic Region and HLH/LZ domains. Chromatin Immunoprecipitation (ChIP) assays 
demonstrate that Myc, Miz1 and Max are associated with the C/EBPδ promoter in proliferating cells, when C/EBPδ 
expression is repressed. EMSAs demonstrate that Miz1 binds to a 30 bp region (-100 to -70) of the C/EBPδ promoter 
which contains a putative transcription initiator (Inr) element. Miz1 functions exclusively as a repressor of C/EBPδ 
promoter activity. Miz1 siRNA expression or expression of a Miz1 binding deficient Myc (MycV394D) construct reduces 
Myc repression of C/EBPδ promoter activity. Max siRNA expression, or expression of a Myc construct lacking the HLH/
LZ (Max interacting) region, also reduces Myc repression of C/EBPδ promoter activity. Miz1 and Max siRNA treatments 
attenuate Myc repression of endogenous C/EBPδ expression. Myc Box II interacting proteins RuvBl1 (Pontin, TIP49) and 
RuvBl2 (Reptin, TIP48) enhances Myc repression of C/EBPδ promoter activity.
Conclusion: Myc represses C/EBPδ expression by associating with the C/EBPδ proximal promoter as a transient 
component of a repressive complex that includes Max and Miz1. RuvBl1 and RuvBl2 enhance Myc repression of C/EBPδ 
promoter activity. These results identify protein interactions that mediate Myc repression of C/EBPδ, and possibly other 
tumor suppressor genes, and suggest new therapeutic targets to block Myc transcriptional repression and oncogenic 
function.
Background
CCAAT/Enhancer Binding Proteinδ (C/EBPδ) is a mem-
ber of the highly conserved C/EBP family of leucine zip-
per DNA binding proteins [1-3]. C/EBPδ gene expression
is increased in nontransformed mammary epithelial cells
(MECs) in response to G0 growth arrest conditions and
IL-6 family cytokine treatment [4-11]. Ectopic C/EBPδ
expression induces growth arrest of mammary epithelial,
prostate and chronic myelogenous leukemia cell lines
[5,12,13]. Conversely, reducing C/EBPδ gene expression
is associated with delayed growth arrest, genomic insta-
bility, impaired contact inhibition, increased cell migra-
tion and increased growth in reduced serum media
[5,14]. In vivo, female C/EBPδ knockout mice exhibit
increased mammary epithelial cell proliferation and
mammary gland ductal hyperplasia [15].
"Loss of function" alterations in C/EBPδ gene expres-
sion have been reported in human and experimental can-
cer. Using Serial Analysis of Gene Expression (SAGE)
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is down regulated in the progression from normal breast
epithelium to advanced breast cancer [16,17]. Other
reports have shown that C/EBPδ gene expression is
reduced in ~30% of primary human breast tumors and in
primary prostate tumors [11,18]. In experimental models,
C/EBPδ expression is reduced in carcinogen-induced
mammary tumors and in ~50% of mammary tumors iso-
lated from MMTV/c-neu transgenic mice [19,20].
Studies addressing the mechanisms underlying loss of
function alterations in C/EBP gene expression demon-
strated that the C/EBPδ gene promoter is silenced by pro-
moter hypermethylation in the SUM-52PE human breast
cancer cell line (26/27 CpGs methylated) and by site-spe-
cific methylation in primary human breast tumor isolates
[11]. C/EBPδ gene expression is also silenced by pro-
moter hypermethylation in primary cervical cancer and
hepatocellular carcinoma (HCC) [21]. In addition to solid
tumors, C/EBPδ gene expression is reduced and the C/
EBPδ promoter is silenced by hypermethylation in the
U937 human lymphoma derived cell line and in ~35% of
lymphoma cells isolated from AML patients [22].
Although C/EBPδ expression is reduced in primary
tumors and cancer derived cell lines inactivating muta-
tions in the intronless C/EBPδ gene are rare [23,24]. This
indicates that alterations in regulatory mechanisms that
control C/EBPδ gene expression play a key role in cancer-
related C/EBPδ "loss of function" alterations. We used
nuclear run-on assays to investigate C/EBPδ transcrip-
tional regulation and found that C/EBPδ gene transcrip-
tion is induced ~6 fold in G0 growth arrested
nontransformed mammary epithelial cells compared to
actively proliferating mammary epithelial cells [6]. These
findings demonstrated the importance of transcriptional
control of C/EBPδ gene expression and suggested that
alterations in transcriptional activators or repressors
would have a major impact on C/EBPδ expression and
cellular growth control.
c-Myc (Myc) is a member of the Myc family of helix
loop helix proteins that function in the activation and
repression of target gene transcription [25]. Myc expres-
sion promotes cell proliferation and Myc over expression
has been documented in a wide range of human cancers
[25]. The Myc gene is frequently amplified in breast can-
cer and experimental studies indicate that Myc is a down-
stream transcriptional effector of ErbB2 receptor tyrosine
kinase activation, a signaling pathway that is commonly
dysregulated and constitutively active in breast cancer
[26,27]. Accumulating evidence indicates that transcrip-
tional repression of Myc target genes is a major mecha-
nism in which Myc promotes cell transformation [28].
Myc represses the transcription of key growth control,
differentiation and tumor suppressor genes including
GAS1, p15INK4, p21CIP1, p27KIP1, p57KIP2, growth arrest
and DNA damage 34 (GADD34), GADD45, C/EBPα and
GADD153 (C/EBPζ) [25,28-42].
We previously reported that the C/EBPδ proximal pro-
moter is in a constitutively "open" chromatin conforma-
tion and that the C/EBPδ proximal promoter is accessible
to activating (Sp1, pSTAT3, CREB) and repressive (Myc)
transcriptional regulatory factors [43]. Myc repression of
C/EBPδ gene transcription may promote mammary tum-
origenesis as C/EBPδ functions as a transcriptional acti-
vator of growth arrest, differentiation, apoptosis and
inflammation related genes [3,44]. Myc repression is
mediated by Myc interactions with promoter-bound
transcriptional control proteins such as Sp1, Smads and
Miz1 [25,44]. In this report, we provide new mechanistic
insights into Myc repression of C/EBPδ gene expression.
We demonstrate that Myc repression of the C/EBPδ pro-
moter is dependent on Myc Box II (MBII), basic region
(BR), helix-loop-helix (HLH) region and the leucine zip-
per (LZ) domains. In addition, we demonstrate that Myc
repression of the C/EBPδ promoter is dependent on Miz1
and Max; two Myc interacting proteins that are constitu-
tively associated with the C/EBPδ proximal promoter.
Miz1 is required for Myc repression of C/EBPδ promoter
activity but Miz1 does not activate the C/EBPδ promoter
in nontransformed mammary epithelial cells. These
results indicate that Miz1 functions exclusively in Myc
mediated repression of C/EBPδ in nontransformed mam-
mary epithelial cells. In addition, endogenous C/EBPδ
expression is increased in cells treated with Miz1 and
Max siRNAs, supporting a role for both Max and Miz1 in
Myc repression of C/EBPδ expression. Finally, RuvBl1
(Pontin, TIP49) and RuvBl2 (Reptin, TIP48), two AAA+
family DNA helicases that interact with Myc Box II,
repress C/EBPδ promoter activity [45]. These results pro-
vide new insights into Myc protein-protein interactions
and the functional roles of Miz1, Max, RuvBl1 and
RuvBl2 in Myc repression of C/EBPδ expression.
Results
Myc represses C/EBPδ promoter activity in nontransformed 
HC11 mammary epithelial cells
To investigate the role of Myc as a repressor of C/EBPδ
gene transcription we first determined Myc and C/EBPδ
protein levels in actively cycling (growing (GR)) and
growth arrested (GA), nontransformed HC11 mammary
epithelial cells. The results confirmed that Myc protein
levels are elevated in growing HC11 cells and reduced in
growth arrested HC11 cells (Figure 1AB). Conversely, C/
EBPδ protein levels are virtually undetectable in growing
HC11 cells and C/EBPδ protein levels are induced in
growth arrested HC11 cells (Figure 1AB). Cyclin D1, a
labile G1/S marker, is elevated in growing HC11 cells and
reduced in growth arrested cells, paralleling Myc protein
levels and confirming HC11 growth (cell cycle) status in
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Figure 1 Myc represses C/EBPδ promoter activation. A. c-Myc (Myc), C/EBPδ, Cyclin D1, Miz1, Max and Sp1 protein levels in HC11 nontransformed 
mouse mammary epithelial cells under exponentially growing (GR) and growth arrest (GA) conditions (Western blot). B. Western blots from "A" were 
scanned to assess relative Myc, C/EBPδ, Cyclin D1, Miz1, Max and Sp1 protein levels in HC11 cells under Growing (Grow) vs Growth Arrest (GA) condi-
tions. Due to differences in antibody affinity, quantitative comparisons are only valid for individual proteins under Grow vs GA conditions. C. HC11 cells 
were co-transfected with increasing amounts of a V5 tagged Myc expression construct (5-50 ng) plus a C/EBPδ promoter luciferase reporter construct. 
C/EBPδ promoter driven luciferase results were normalized to co-transfected Renilla luciferase control activity. Luciferase results from Myc treated cells 
are expressed relative to the vector control results, which were set as "1". D. Whole cell lysates (20 ul) from (C.) were immunoblotted and probed with 
an anti-V5 antibody to assess V5-tagged Myc protein levels in vector control (grey bar) and Myc transfected (black bar) HC11 cells. E. Schematic rep-
resentation of Myc full length and Myc deletion mutants. Full length c-Myc contains: Myc box 1 (MB1, 45-63aa), MB2 (129-143aa), nuclear localization 
signal (NLS, 320-328aa), basic region (BR, 355-367aa), helix-loop-helix (HLH, 368-410aa) and leucine zipper (LZ, 411-439aa). F. HC11 cells were co-trans-
fected with a C/EBPδ promoter luciferase reporter construct plus full length Myc or Myc deletion mutant expression constructs (V5 tagged). C/EBPδ 
promoter driven luciferase activities were normalized to co-transfected renilla luciferase control activity. C/EBPδ promoter driven luciferase results 
from Myc constructs are expressed relative to the vector control results, which were set as "1". G. Whole cell lysates from luciferase assays in (D.) were 
immunoblotted and probed with an anti-V5 antibody to assess Myc and Myc deletion mutant protein levels. All luciferase results shown are the aver-
age-fold changes relative to the vector control values from 2-3 independent experiments with duplicates performed in each experiment.
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and Max are also present at relatively constitutive levels
in growing and growth arrested HC11 cells (Figure 1AB).
Induction of C/EBPδ gene transcription requires the
transcriptional activator Sp1 [7,48,49]. Sp1 protein levels,
however, are unaffected by cell cycle status (Figure 1AB).
These results demonstrate that Myc and C/EBPδ protein
levels are directly influenced by growth status and that
Myc and C/EBP protein levels are inversely correlated in
nontransformed HC11 mammary epithelial cells.
To investigate Myc repression of C/EBPδ promoter
activity, HC11 cells were transfected with increasing
amounts of Myc (5~50 ng) plus a C/EBPδ promoter
luciferase construct (Figure 1C). Myc repressed C/EBPδ
promoter activity in a dose-dependent manner, even at
dose levels as low as 5 ng (Figure 1C). Expression of Myc
constructs was confirmed by Western blot analysis of cell
lysates (Figure 1D). To map the domains of Myc essential
for the repression of C/EBPδ promoter activity, Myc dele-
tion mutants corresponding to Myc box 1 (ΔMB1, 45-63),
Myc box 2 (ΔMB2, 129-143), basic region (ΔBR, 355-
367), helix-loop-helix (ΔHLH, 368-410) and leucine zip-
per (ΔLZ, 411-439) were constructed (Figure 1E). The full
length Myc construct and the Myc MB1 deletion mutant
both repressed C/EBPδ promoter activity to ~50% of the
empty vector control. These results indicate that the Myc
MB1 deletion mutant is nearly as effective as the full
length Myc construct in repressing C/EBPδ promoter
activity and therefore, the Myc MB1 region is not
required for Myc repression of C/EBPδ promoter activity
(Figure 1F). In contrast, the Myc MB2, BR, HLH and LZ
deletion mutants all resulted in C/EBPδ promoter activity
that was similar to the empty vector control (Figure 1F).
These results demonstrate that the MB2, BR, and the
HLH/LZ regions are required for Myc repression of C/
EBPδ promoter activity. Western blots demonstrated that
the protein levels of the individual transfected Myc con-
structs were approximately equal; indicating that differ-
ences in C/EBPδ promoter activity were not due to
variations in the expression of the transfected Myc con-
structs (Figure 1G).
Miz1 (Myc-interacting zinc-finger protein1) is constitutively 
associated with the C/EBPδ promoter; Myc interacts with 
Miz1 in the repression of C/EBPδ promoter activity
Myc represses gene promoters by interacting with DNA
bound transcription factors including Sp1 and Miz1 [44].
To identify the Myc interacting protein implicated in Myc
repression of the C/EBPδ promoter we transfected HC11
cells with V5-tagged Myc expression constructs and per-
formed co-immunoprecipitations to assess Myc/Miz1
and Myc/Sp1 interactions in HC11 cell lysates. The
results demonstrated that Myc interacts with Miz1, but
not Sp1, supporting a role for Myc/Miz1 repression of the
C/EBPδ promoter (Figure 2A). We next used ChIP assays
to investigate the association between Myc and Miz1 and
the C/EBPδ proximal promoter (P200) in Growing ("Gr",
C/EBPδ non-expressing) and growth arrested ("GA", C/
EBPδ expressing) HC11 cells. The ChIP results demon-
strated that both Myc and Miz1 associate with the C/
EBPδ proximal (P200) promoter in HC11 cells under
Growing ("Gr", C/EBPδ non-expressing) conditions (Fig-
ure 2B). Miz1 remains associated with the C/EBPδ proxi-
mal (P200) promoter under growth arrest ("GA", C/EBPδ
expressing) but Myc is not associated with the C/EBPδ
proximal (P200) promoter in growth arrested (GA) HC11
cells (Figure 2B). Regardless of the growth conditions,
neither Miz1 nor Myc is associated with the distal C/
EBPδ promoter region located 1.8 kb upstream of the C/
EBPδ transcription start site (P1.8K) (Figure 2B). These
results are consistent with the presence a Myc/Miz1 com-
plex in association with the C/EBPδ proximal promoter
during active cell proliferation when C/EBPδ gene tran-
scription is repressed and the absence of Myc in associa-
tion with the C/EBPδ proximal promoter during growth
arrest when C/EBPδ gene transcription is highly induced
[6]. The negative ChIP results from the distal C/EBPδ
promoter region 1.8 kb upstream of the C/EBPδ tran-
scription start site (P1.8K) indicate that the Myc repres-
sive complex is localized to C/EBPδ proximal (P200)
region.
To determine if Myc/Miz1 interaction is required for
Myc repression of C/EBPδ promoter activation we
obtained a mutant Myc construct that is deficient in Miz1
binding (MycV394D, Val394 T Asp, generous gift from Dr.
M. Eilers). To validate the MycV394D Miz1 binding
defect co-immunoprecipitation assays were performed
on HC11 cells transfected with V5 tagged Myc wild type
(wt) or the MycV394D (Miz1 binding deficient) con-
structs. The results demonstrated that the Myc wt con-
struct (myc) binds to Miz1, but the Myc V394D construct
("394") does not (Figure 2C). To assess the functional sig-
nificance of Myc/Miz1 binding on Myc repression of C/
EBPδ promoter activity HC11 cells were transfected with
Myc wt or the MycV394D Miz1 binding deficient mutant
plus a C/EBPδ proximal (P200) promoter-luciferase con-
struct. The results demonstrated that the Miz1 binding
deficient MycV394D mutant construct was relatively
ineffective in repressing C/EBPδ promoter activity com-
pared to the Myc wt construct (Figure 2D). Western blots
documented the expression of transfected Myc con-
structs (Figure 2E). These results demonstrate that opti-
mal Myc repression of C/EBPδ promoter activity requires
Miz1.
Miz1 does not activate the C/EBPδ promoter in 
nontransformed HC11 mammary epithelial cells
Previous reports have demonstrated that Miz1 functions
as a transcriptional activator and that Myc represses
Miz1 target gene activation [39]. Miz1 is associated with
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(Figure 2B above) when C/EBPδ is actively transcribed
[6], suggesting that Miz1 may function as a transcrip-
tional activator of C/EBPδ transcription. To investigate
Miz1 transcriptional activation of the C/EBPδ promoter
HC11 cells were co-transfected with a Miz1 expression
construct plus a C/EBPδ proximal promoter-luciferase
(P200) construct. The results demonstrate that Miz1
expression does not increase C/EBPδ promoter activity in
proliferating (growing, Gr), or in growth arrested (GA)
HC11 cells (Figure 3A). As expected, C/EBPδ promoter
activity is higher in growth-arrested vs growing HC11
cells [6,7]. Western blot analysis of HC11 cell lysates dem-
onstrate the increased levels of Miz1 in HC11 cells trans-
fected with the Miz1 expression construct and confirm
the presence of Myc protein levels in growing (Gr) cells
and the absence of Myc in growth arrested (GA) cells
(Figure 3B).
Although Miz1 over expression had no effect on C/
EBPδ promoter activity, reducing Miz1 levels by Miz1
siRNA treatment had a profound effect on C/EBPδ pro-
moter activity in growing (Gr) HC11 cells. C/EBPδ pro-
moter activity was induced ~2.5 fold in Miz1 siRNA
treated; growing (Gr) HC11 cells (Figure 3C). Reducing
Miz1 levels, however, had no effect on C/EBPδ promoter
activity in growth arrested (GA) HC11 cells (Figure 3C).
These results indicate that reducing Miz1 levels increases
C/EBPδ promoter activity in proliferating cells, presum-
Figure 2 Myc interacts with Miz1; Miz1 plays a key role in Myc repression of C/EBPδ promoter activity. A. HC11 cell lysates were immunopre-
cipitated with anti-Myc and anti-Miz1 antibodies and the immunoprecipitates analyzed by Western blot using anti-Myc, Miz1 and Sp1 antibodies. "In-
put": western blot analysis of HC11 whole cell lysates (positive control). "IgG": nonspecific rabbit IgG immunoprecipitates (negative control). B. HC11 
cell chromatin was immunoprecipitated using antibodies against Myc or Miz1. Immunoprecipitated DNA was amplified using primers flanking the C/
EBPδ proximal (P200) promoter region and the distal (P1.8K) C/EBPδ upstream promoter regions. "Input" results are derived from direct PCR amplifi-
cation of P200 and P1.8K C/EBPδ promoter regions from HC11 genomic DNA (Positive control). IgG: nonspecific rabbit IgG immunoprecipitated (neg-
ative control). C. HC11 cells were transfected with vector control, Myc wt or Myc V394D expression constructs (V5-tagged). Co-immunoprecipitation 
was performed using an anti-V5 antibody. Immunoprecipitates were analyzed by Western blot using anti-Miz1 and anti-V5 antibodies. D. HC11 cells 
were co-transfected with a C/EBPδ promoter luciferase reporter construct, vector control, Myc wild type (wt) or Myc V394D. C/EBPδ promoter driven 
luciferase activities were normalized to renilla luciferase activity. Results for the Myc transfected cells are expressed relative to the vector control results 
which were set as "1". E. Whole cell lysates (20 ul) from lucifease assays in (D.) were analyzed by Western blot to assess Myc wt and Myc V394D expres-
sion. Luciferase results shown are the average-fold changes relative to the vector control values from 2 independent experiments with duplicates per-
formed in each experiment.
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estingly, C/EBPδ promoter activity is not altered by
reducing Miz1 levels in growth arrested HC11 cells (Fig-
ure 3C). These results indicate that Miz1 does not
increase C/EBPδ promoter activity during growth arrest.
Western blot analysis of HC11 cell lysates confirmed that
siRNA treatment was highly effective in reducing Miz1
protein levels (Figure 3D). To verify that Miz1 can func-
tion as a transcriptional activator in the proper cell con-
text HEPG2 cells were transfected with a Miz1 expression
construct plus a low-density lipoprotein receptor (LDLR)
promoter-luciferase construct essentially as described by
Tjian and co-workers [50]. The results demonstrated that
Miz1 functions as a transcriptional activator of the LDLR
promoter in HEPG2 cells (Figure 3E). These results dem-
onstrate that Miz1 functions exclusively in Myc repres-
sion of C/EBPδ promoter activity under growing
(proliferating) conditions but Miz1 does not activate C/
EBPδ promoter activity in growth arrested HC11 non-
transformed mammary epithelial cells.
Figure 3 Miz1 functions in Myc repression of C/EBPδ promoter activity. A. HC11 cells were co-transfected with Miz1 or a vector control plus a C/
EBPδ promoter luciferase construct and Renilla control. Luciferase activity was assessed under Growing (Gr) (Myc expressed, C/EBPδ repressed) or 
growth arrest (GA) (Myc not expressed, C/EBPδ expressing) conditions. Luciferase results were normalized to the Renilla control. C/EBPδ promoter 
driven luciferase results from Miz1 transfected cells are expressed relative to the vector control, "Gr" results which were set as "1". B. Lysates from lu-
ciferase assays (A.) were analyzed by Western blot to assess Myc and Miz1 protein levels. β-actin levels were assessed as a loading control. C. HC11 
cells were transfected with Miz1 siRNA treatment and C/EBPδ promoter driven luciferase assays performed as described. Luciferase results were nor-
malized to the Renilla control. C/EBPδ promoter driven luciferase results from Miz1 siRNA treated cells are expressed relative to the vector control, "Gr" 
results which were set as "1". D. Lysates from luciferase assays (C.) were analyzed by Western blot to assess Myc and Miz1 protein levels. β-actin levels 
were assessed as a loading control. Luciferase results for the Miz1 expression and Miz1 siRNA treatment groups shown are the average-fold changes 
relative to the "scrambled" siRNA values from 2 independent experiments with duplicates performed in each experiment.  E. HEPG2 cells were co-
transfected with Miz1 or a vector control plus a low density lipoprotein receptor (LDLR) promoter luciferase construct and Renilla control. Luciferase 
results were normalized to the Renilla control. LDLR promoter driven luciferase results from Miz1 transfected cells are expressed relative to the vector 
control results which were set as "1".
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promoter
Myc functions as a transcriptional repressor by binding
to DNA-bound Miz1 [28]. Miz1 binds to highly divergent
proximal promoter transcription initiator (Inr) elements
[28]. To investigate Miz1 binding to the C/EBPδ pro-
moter we performed electromobility shift assays
(EMSAs) using recombinant mouse Miz1 and fluorescent
labeled C/EBPδ proximal promoter fragments. The initial
results confirmed Miz1 binding to the -140 to +30 C/
EBPδ proximal promoter (Figure 4A). To localize the
region of Miz1 binding we performed EMSAs using C/
EBPδ promoter fragments deleted from the 3' and 5'
ends. Miz1 binding was retained in all C/EBPδ proximal
promoter fragments deleted from the 3' end, indicating
that Miz1 binding was localized within -140 to -70 region
of the C/EBPδ proximal promoter (Figure 4B). Deletions
from the 5' of the C/EBPδ proximal promoter indicated
that the Miz1 binding was localized within the -110 to -80
region of the C/EBPδ proximal promoter (Figure 4C,
lanes f, g). To further investigate Miz1 binding EMSAs
were performed with recombinant Miz1 protein and
short (~30 bp) C/EBPδ proximal promoter fragments
spanning the following regions of the C/EBPδ proximal
promoter: -127 to -100 bp (Probe "h"), -100 to -70 bp
(Probe "i") and +1 to +30 (Probe "j", a negative EMSA
control). The results demonstrated weak Miz1 binding to
the -127 to -100 region ("h"), strong Miz1 binding to the -
100 to -70 region ("i"), and no detectable Miz1 binding to
the +1 to +30 region ("j") (Figure 5A). We next performed
individual competition assays with the same 3 C/EBPδ
promoter fragments and the C/EBPδ -140 to +30 proxi-
mal promoter fragment. The results demonstrated that
the -100 to -70 ("i") C/EBPδ promoter fragment was the
most effective in reducing Miz1 binding to the C/EBPδ -
140 to +30 proximal promoter fragment (Figure 5B). The
-127 to -100 C/EBPδ promoter exhibited a limited capac-
ity to compete with the C/EBPδ -140 to +30 proximal
promoter fragment for Miz1 binding, consistent with the
weak binding to this region demonstrated in Figure 5A.
Although Inr sequences are highly degenerate, a candi-
date Inr sequence is located at -85 to -93 (5'-CCCCA-
GTCCCT-3') of the C/EBPδ proximal promoter, within
the -100 to -70 region [6].
Max is constitutively associated with the C/EBPδ promoter 
and functions in the repression of C/EBPδ promoter activity
Myc Associated protein X (Max) is a ubiquitously
expressed, long lived (t 1/2 > 24 hours) helix loop helix/
leucine zipper (HLH/bZIP) protein that heterodimerizes
with Myc and is required for Myc transcriptional activa-
tion and repression [51-53]. Using ChIP assays, we
assessed the association between Max and the C/EBPδ
promoter under growing and under growth arrest condi-
tions. The results indicated that Max is associated with
the C/EBPδ promoter under both growing (GR, C/EBPδ
expression repressed) and growth arrest (GA, C/EBPδ
expression highly induced) conditions (Figure 6A). To
determine if Max is required for Myc repression of C/
EBPδ promoter activity HC11 cells were treated with
Max siRNA and C/EBPδ promoter driven luciferase
activity assessed. The results indicated that Max siRNA
treatment reduces Myc repression of C/EBPδ promoter
activity and this reduction in Myc repression is compara-
ble to Miz1 siRNA treatment (Figure 6B). These results
demonstrate that Max is constitutively associated with
the C/EBPδ promoter and plays a key role in Myc repres-
sion of C/EBPδ promoter activity.
IL-6 and Oncostatin M (OSM) induce STAT3 activa-
tion (phosphorylation) and phosphorylated STAT3
(pSTAT3) activates C/EBPδ transcription in growth
arrested cells [7,8,54]. OSM activates pSTAT3, but
pSTAT3 does not fully activate C/EBPδ expression in
proliferating (growing) cells due to Myc repression [43].
Myc repression of OSM induced endogenous C/EBPδ
expression is attenuated by Myc siRNA treatment [43].
To investigate the role of Max and Miz1 in Myc repres-
sion of endogenous C/EBPδ expression HC11 cells were
transfected with Max and Miz1-specific siRNAs. Endoge-
nous C/EBPδ expression was assessed by western blot of
whole cell lysates from actively proliferating (growing)
vector control, Max and Miz1 siRNA treated HC11 cells
treated with OSM. The results demonstrated that Max
and Miz1 siRNA treatments reduced endogenous Max
and Miz1 protein levels and the individual reductions in
Max and Miz1 protein levels were associated with
increased OSM-induced C/EBPδ protein levels compared
to scrambled or "Junk" siRNA treated HC11 cells (Figure
6C). These results indicate that Max and Miz1 function
in repression of endogenous C/EBPδ gene expression.
RuvBl1(Pontin, TIP49) and RuvBl2 (Reptin, TIP48) repress C/
EBPδ promoter activity
RuvBl1 (Pontin, TIP49) and RuvBl2 (Reptin, TIP48) are
members of the highly conserved AAA+ (ATPases asso-
ciated with diverse cellular activities) superfamily with
functions in chromatin remodeling and transcriptional
regulation [45]. We hypothesized that RuvBl1 (Pontin,
TIP49) and RuvBl2 (Reptin, TIP48) may contribute to
Myc repression of C/EBPδ promoter activity as both pro-
teins interact with Myc Box II and enhance Myc tran-
scriptional repression and Myc mediated transformation
[25,34,53,55]. In addition, RuvBl1 (Pontin) and RuvBl2
(Reptin) are overexpressed in a variety of human cancers
[45]. To investigate the role of RuvBl1 and RuvBl2 in Myc
repression of C/EBPδ promoter activation RuvBl1 and
RuvBl2 expression constructs were transfected into pro-
liferating HC11 cells and C/EBPδ promoter activity
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Figure 4 Miz1 binds to the C/EBPδ proximal promoter. A. Miz1 binds to the C/EBPδ promoter (170 bp, -140 to +30). Lanes: (1) C/EBPδ 170 bp pro-
moter fragment; (2) Miz1 (5 ng) + C/EBPδ 170 bp promoter fragment; (3) Miz1 (15 ng) + C/EBPδ 170 bp promoter fragment; (4) Miz1 (5 ng). B. Miz1 
binds to the C/EBPδ promoter 5' region. Lanes: a. C/EBPδ promoter fragment (-140 to +30), - or + Miz1 (5 ng); b. C/EBPδ promoter fragment (-140 to 
-10), - or + Miz1; c. C/EBPδ promoter fragment (-140 to -40), - or + Miz1; d. C/EBPδ promoter fragment (-140 to -70), - or + Miz1. C. Miz1 does not bind 
to C/EBPδ promoter fragments with the -110 to -80 region deleted. Lanes: a. C/EBPδ promoter fragment (-140 to +30), - or + Miz1 (5 ng); e. C/EBPδ 
promoter fragment (-110 to +30), - or + Miz1; f. C/EBPδ promoter fragment (-80 to +30), - or + Miz1; g. C/EBPδ promoter fragment (-50 to +30), - or + 
Miz1. Results are representative of 3 EMSA experiments.
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Page 9 of 15assessed by luciferase assay. The results demonstrated
that both RuvBl1 and RuvBl2 repress C/EBPδ promoter
activity in a dose-dependent manner (Figure 7A). In addi-
tion to assessing the repressive effects of RuvBl1 and
RuvBl2 individually, the repressive effect of co-transfect-
ing RuvBl1 and RuvBl2 on C/EBPδ promoter activity was
also investigated. The results demonstrated that co-
expression of RuvBl1 and RuvBl2 was more effective in
repressing C/EBPδ promoter activity than expression of
either RuvBl1 and RuvBl2 alone (Figure 7A). Western blot
analysis documented the expression of the transfected
constructs and the positive correlation between increased
RuvBl1 and RuvBl2 expression levels and increased
repression of C/EBPδ promoter activity (Figure 7B).
Discussion
The findings from this study demonstrate that Myc
represses C/EBPδ expression by associating with the C/
EBPδ proximal promoter as transient component of a
multi-protein repressive complex. Transcriptional
repression is a major mechanism of Myc oncogenesis and
Myc repressed genes include critical regulators of cell
cycle progression, growth arrest and differentiation such
as p21CIP1, p27KIP1, p15INK4, p18INK4c, p57KIP2, gas1, and C/
EBPα [44]. Myc repression of C/EBPδ transcription is
Miz1 dependent, indicating that Myc repression of C/
EBPδ transcription parallels Myc repression of p15INK,
p21CIP1, p27KIP1, Mad4 and C/EBPα [25]. However, Miz1
does not function as a transcriptional activator of the C/
EBPδ promoter in nontransformed mammary epithelial
cells, differentiating Miz1 function in the regulation of C/
EBPδ from p15INK, p21CIP1 and Mad4 [44]. Although
Miz1 does not activate the C/EBPδ promoter, ChIP assays
demonstrated that Miz1 is constitutively associated with
the C/EBPδ promoter. EMSA analysis localized the Miz1
binding site to the -100 to -70 region of the C/EBPδ prox-
imal promoter. This a region contains a candidate Inr (-85
to -93) immediately downstream of STAT3/Sp1 consen-
sus sites (-120 to -104) that are associated with C/EBPδ
transcriptional activation [7,54]. We and others have
reported that pSTAT3 is a potent transcriptional activa-
tor of C/EBPδ gene expression [7,8]. The presence of the
Miz1 binding site downstream of the C/EBPδ consensus
transcriptional activation sites provides a rationale for
how Myc represses C/EBPδ expression in actively cycling
cells that exhibit increased pSTAT3 in response to IL-6
family cytokines [43]. These findings suggest that Myc
repression of C/EBPδ expression could contribute to the
cascade of Myc mediated events that result in aberrant
cell proliferation and enhanced transformation.
Figure 5 Miz1 binding is localized to the -100 to -70 region of the C/EBPδ proximal promoter (Probe "i"). A. EMSAs were performed without 
Miz1 (-) or with Miz1 (+) (5 ng) plus the following C/EBPδ proximal promoter fragments: -127 to -100 bp (Probe "h"); -100 to -70 (Probe "i"); or +1 to 
+30 (Probe "j") - or + Miz1 (5 ng). B. Competition EMSAs: C/EBPδ -100 to -70 proximal promoter fragment (Probe "i") effectively competes for Miz1 
binding with the "full length" -140 to +30 C/EBPδ proximal promoter fragment. Miz1 was incubated with the "full length" -140 to +30 C/EBPδ proximal 
promoter fragment (Probe "a") plus 5×, 10× and 25× molar excess of C/EBPδ proximal promoter fragments: -127 to -100 bp (Probe "h"); -100 to -70 
(Probe "i"); or +1 to +30 (Probe "j"). Results are representative of 2 EMSA experiments.
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Page 10 of 15Max, a well-established Myc binding partner, also plays
a key role in Myc repression of C/EBPδ expression. Like
Miz1, Max is constitutively associated with the C/EBPδ
promoter even in the absence of Myc, a finding that is
consistent with a previous report by Mao, et al, [52]. The
recruitment of Miz1 and Max to the C/EBPδ proximal
promoter may be facilitated by the C/EBPδ proximal pro-
moter "open" chromatin conformation [43]. We previ-
ously reported that the C/EBPδ proximal promoter is in
an open chromatin conformation and "pre-loaded" with
transcriptional machinery components associated with
transcriptional activation including Sp1, cyclic AMP
response element-binding protein (CREB), TATAA Bind-
ing protein (TBP) and RNA Pol II [43]. The present
results demonstrate that Miz1 and Max, two proteins that
function in C/EBPδ transcriptional repression, are also
constitutively associated with the C/EBPδ promoter.
These results are consistent with a model in which the C/
EBPδ proximal promoter exists in a unique state, poised
for activation or repression by the constitutive presence
of proteins that mediate both transcriptional activation
and repression.
Although Myc transcriptional repression is critical for
Myc mediated cell transformation, the proteins that
interact with Myc and function in gene repression are
poorly characterized. RuvBl1 (Pontin, TIP49) and RuvBl2
(Reptin, TIP48) are two AAA+ ATPase helicases that
interact with Myc Box II and function in Myc transcrip-
tional repression, and have been shown to increase cell
proliferation and transformation [55-57]. Individually,
Figure 6 Max is required for Myc repression of the C/EBPδ promoter activity. A. ChIP assays were performed on chromatin isolated from growing 
(GR) and Growth arrest (GA) HC11 cells using anti-Max antibodies. Immunoprecipitated DNA was amplified using primers flanking the C/EBPδ proxi-
mal promoter region (P200) and the C/EBPδ upstream promoter region (P1.8K). "Input" results are derived from PCR amplification of HC11 genomic 
DNA. Normal rabbit IgG was used as negative control. B. Growing HC11 cells were nucleofected with the "scrambled" siRNA control, Miz1 siRNA and 
Max siRNA. C/EBPδ promoter-luciferase results were normalized to the Renilla control. The luciferase results for the "scrambled" siRNA control were 
set as "1". Luciferase results for the Miz1 and Max siRNA treatment groups shown are the average-fold changes relative to the "scrambled" siRNA con-
trol values from 3 independent experiments with duplicates performed in each experiment (n = 6). C. HC11 cells were nucleofected with a scrambled 
siRNA, Max or Miz1 siRNA constructs using the Amaxa nucleofector protocol. Nucleofected HC11 cells were then cultured in complete growth media 
(proliferating, growing conditions) in the presence of OSM (GROW + OSM). Whole cell lysates were isolated and analyzed by Western blot using anti- 
C/EBPδ, Max and Miz1 antibodies (lane 1-3). β-actin was assessed as the loading control. The results shown are representative of three independent 
experiments.
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Page 11 of 15both RuvBl1 and RuvBl2 repressed C/EBPδ promoter
activity, however, co-expression of RuvBl1 and RuvBl2
was most effective in repressing C/EBPδ promoter activ-
ity. This suggests that Myc transcriptional repression of
C/EBPδ may be mediated by a multi-protein complex
composed of DNA bound Miz1, Myc/Max and possibly
RuvBl1 and RuvBl2. Studies in Xenopus demonstrated
that RUVBL1/RUVBL2 (xPontin/xReptin) induce cell
proliferation during embryogenesis by enhancing Myc
repression of p21 [58]. Our findings suggest that a similar
mechanism may mediate Myc repression of C/EBPδ and
possibly other growth suppressor genes (such as p21Waf1/
CIP1), in promoting aberrant mammary epithelial cell pro-
liferation and transformation.
Despite the critical role of Myc transcriptional repres-
sion in cell transformation, the mechanism by which Myc
transcriptional repression leads to cell transformation is
poorly understood. Several lines of evidence indicate that
Myc can recruit DNA methyltransferases and that Myc
transcriptional repression can progress to transcriptional
silencing. For example, Myc repression of p21Waf1/CIP1
transcription in human U2OS osteosarcoma cells occurs
via formation of a repressive complex including Myc,
Miz1 and DNA Methyltransferase3a (Dnmt3a) [59]. In
addition, studies in human cervical and hepatocellular
carcinoma cells have shown recruitment of DNA methyl-
transferases and silencing of the human C/EBPδ
(CEBPD) promoter by hypermethylation [21]. Our lab
reported that the C/EBPδ gene is silenced by promoter
hypermethylation in the SUM-52PE human breast cancer
cell line and that primary breast tumors exhibiting
reduced C/EBPδ expression are characterized by site-
Figure 7 RuvBl1 and RuvBl2 repress C/EBPδ promoter activity. A. Exponentially growing HC11 cells were co-transfected with vector control (VC) 
or increasing amounts (20, 50 100 μg) of FLAG-tagged RuvBl1 (TIP49, Pontin), RuvBl2 (TIP48, Reptin) or RuvBl1/RuvBl2 combined plus the C/EBPδ prox-
imal promoter-luciferase and the Renilla control. Luciferase results were normalized to the Renilla control, the VC values were set as "1" and the RuvBl1 
and RuvBl2 transfected cell luciferase results are expressed relative to the VC control. B. Lysates from luciferase assays (A.) were analyzed by Western 
blot to using an anti-FLAG antibody to assess Myc and Miz1 protein levels. β-actin levels were assessed as a loading control. All luciferase results shown 
are from 3 independent experiments with duplicates performed in each experiment.
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Page 12 of 15specific promoter methylation [10,11,54]. The results
from this study demonstrate that Myc repression of C/
EBPδ transcription is a regulated process that is coordi-
nated with cell cycle status in nontransformed cells. Fur-
ther studies are needed to determine how this regulated
Myc repression function is altered and progresses to gene
silencing and cell transformation.
Conclusion
The results of this study identify protein-protein and
DNA-protein interactions that mediate Myc repression of
C/EBPδ gene expression. These results extend current
working models of Myc transcriptional repression and
suggest future directions to pursue in the characteriza-
tion of the network of proteins that function in Myc tran-
scriptional repression. The results presented have
focused on Myc repression of the mouse C/EBPδ pro-
moter in HC11 mouse nontransformed mammary epi-
thelial cells; however, human Myc expression constructs
also repress the human C/EBPδ promoter in nontrans-
formed human mammary epithelial cells (MCF-10A)
(data not shown). Current experiments are focused on
further characterizing Myc interacting proteins, deci-
phering the sequence of events that mediate Myc repres-
sion of C/EBPδ in nontransformed mouse and human
cells, and determining how this sequence progresses to
gene silencing and cell transformation. Defining the pro-
tein interactions that mediate Myc repression, and the
role of Myc in the silencing of tumor suppressor genes,
will facilitate the development of pharmacological inter-
ventions to inhibit the functions of Myc that promote cell
transformation.
Methods
Cell Culture
HC11 mouse mammary epithelial cells were grown in
complete growth media (CGM) containing RPMI 1640
medium plus 5% fetal bovine serum (FBS), 10 μg/ml
bovine insulin, 10 ng/ml epidermal growth factor, 100 U/
ml penicillin, 100 μg/ml streptomycin and 500 ng/ml
Fungizone. Growth arrest was induced by 24~48 hrs
serum and growth factor withdrawal (growth arrest
medium, GAM, 0.1% FBS).
Plasmid Constructs
Mouse C/EBPδ proximal promoter sequence flanking -
127 bp to transcriptional start site (P-127, containing Sp1,
STAT3 and CREB binding sites) was constructed in the
pGL2 basic luciferase reporter vector [7,60]. Myc and
MycV394D mutant constructs in pBabe-puro vector were
a generous gift from Dr. Martin Eilers (Institute for
Molecular Biology and Tumor Research, University of
Marburg, Germany). Myc and MycV394D were then
amplified by PCR from pBabe-puro vector using primers
specific for Myc. The primer sequences for Myc wild type
and MycV394D cloning are as follows: 5'-CGCGGATC-
CGCGATGCCCCTCAACGTTAGCTTC-3' (forward
primer) and 5'-GCTCTAGACGCGCACAAGAGTTC-
CGTAGCTG-3' (reverse primer). Myc deletion con-
structs MycΔ45-63(MB1), MycΔ129-143(MB2),
MycΔ355-367(BR), MycΔ368-410(HLH) and MycΔ411-
439(LZ) were constructed by site-specific mutagenesis as
previously described [61,62]. Myc-, Myc deletion- and
V394D- pcDNA3.1-V5-His expression constructs were
verified by sequencing. The Miz1 full length cDNA con-
struct in pCMV6 vector was purchased from Origene.
Transfection Protocol
HC11 cells were plated in 12-well plates, grown to 50%
confluence in CGM and transfected using the enhanced
Lipofectamine transfection protocol (Invitrogen, Carls-
bad, CA) as previously described [60]. Co-transfections
were performed with 0.3 ug C/EBPδ promoter luciferase
reporter construct, 1 ng Renilla luciferase reporter con-
struct (transfection efficiency control), and 5~50 ng of
expression constructs or vector controls. For growth
arrest experiments, transfected cells were washed 2× with
PBS and cultured in GAM for 24-48 hours. Cells were
harvested and assayed for firefly and renilla luciferase
activities using the Dual-Luciferase Reporter Assay kit
with luciferase detection by Hewlett-Packard Lumicount
microplate luminometer as previously described [43]. C/
EBPδ promoter activities were normalized to renilla
luciferase activity. Results shown are the average-fold
changes from 3 independent experiments with dupli-
cates. Co-immunoprecipitation experiments were per-
formed as described [43,61,62]. HC11 cell lysates used in
co-immunoprecipitation assays were prepared by trans-
fecting Myc or V394D Myc mutant expression constructs
(1 μg) (Lipofectamine) into HC11 cells. HC11 Miz1 and
Max siRNA transfections were performed using the
Amaxa Nucleofector (Amaxa, Inc., Cologne, Germany).
Briefly, HC11 cells were suspended in Amaxa Nucleofec-
tor Solution V supplemented with 50 pmol Miz1 or Max
Smartpool siRNAs (Dharmacon, Inc., Lafayette, CO) and
the nucleofection was performed using cell-type specific
protocol (T-20). HC11 cells nucleofected with non-spe-
cific scrambled siRNAs were used as controls. Transient
siRNA nucleofection protocols were optimized and pro-
tocols achieving >80% specific gene knockdown as veri-
fied by western blot were used in all experiments.
Western blot and co-immunoprecipitation assays
Western blots were performed on whole cell lysates as
previously described [61,62]. Co-immunoprecipitation
assays were performed with HC11 cell lysates isolated by
NP-40 lysis, primary antibody immunoprecipitation, Pro-
tein A-Agarose bead pull down, elution and analysis by
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cipitations were performed 2-3 times and representative
results presented.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed using the Chromatin
Immunoprecipitation (ChIP) Assay Kit (Sigma) as previ-
ously described [3,43]. Briefly, HC11 cells were cross-
linked with 1% formaldehyde, washed 3× with cold PBS
(4°C), and the nuclear pellets were collected by centri-
fuge. Nuclear pellets were then resuspended in 300 μl
DNA shearing buffer containing protease inhibitor cock-
tail, sonicated on ice to approximately 200~1000 bp (veri-
fied by standard agarose gel analysis), centrifuged at
14000 rpm for 10 minutes to pellet cell debris and the
supernatants were collected and diluted 1:1 in dilution
buffer and used for DNA immunoprecipitation. 10 ul
diluted supernatant was used as input control. One μg of
Myc or Miz1 specific IgG immunoprecipitated protein-
DNA complexes were isolated and protein-DNA cross-
links reversed (65°C, 2 hours). After purification, immu-
noprecipitated DNA was analyzed by PCR using primers
specific for proximal and distal mouse C/EBPδ promoter
[60]. Primer sequences are as follows: P200 (region -226
to -24 of the mouse C/EBPδ promoter containing STAT3
and SP1 binding sites), 5'-GCGTGTCGGGGCCA-
AATCCA-3'(forward primer), 5'-TTTCTAGCCCCA-
GCTGACGCGC-3'(reverse primer); P1.8K (region -1856
to -1676 of the promoter) as control, 5'-TGCTTCTATG-
GCATCCAG-3'(forward primer), 5'-GAGGGGCTGTG-
GAATATT-3'(reverse primer).
Miz1 protein purification
Full length Miz1 cDNA was cloned into pGEX-4T-1 vec-
tor (Miz1-GST). The Miz1-GST plasmid was trans-
formed to BL21 (DE3) competent cell (Stratagene). The
Miz1-GST protein was purified by affinity binding using
Glutathione sepharose beads (GE Healthcare) following
the manufacturer's protocol. Miz1 protein was confirmed
by western blot with detection using Miz1 and GST anti-
bodies (Santa Cruz, Biotechnology).
Electromobility Shift Assay (EMSA)
DNA probes (a to g) were generated by PCR using mouse
C/EBPδ promoter (1.7 kb fragment) as template. Primer
sequences are available upon request. Double stranded
oligos used to produce Probes h, j, and i were purchased
(Sigma). Probes used in EMSA reactions were 5' end-
labeled with 6-FAM (6-Carboxyfluorescein, Sigma).
EMSAs were performed by incubating labeled probes (20
ng) with purified Miz1 protein in binding buffer (10 mM
Tris pH 7.9, 4 mM MgCl2, 5% glycerol, 0.1 mM DTT, 20
ng/μl poly(dI:dC) and 0.2% NP-40) for one hour at room
temperature. To perform EMSA competition assays unla-
belled probes were pre-incubated with Miz1 in binding
buffer for 10 min prior to addition of the labeled probe.
The concentration of unlabeled probes used was 5-25-
fold molar excess over labeled probe. Following incuba-
tion, samples were loaded onto a 4.5% native acrylamide
gel (pre-run for one hour) and electrophoresed for one
hour at 100 V. Gels were scanned using the Typhoon 9410
imager (GE healthcare).
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